Disclosures
Identification and Mitigation of Relevant Financial Relationships
In accordance with The Standards for Integrity and Independence in Accredited Continuing Education promulgated by the Accreditation Council for Continuing Medical Education (“ACCME”), it is the policy of Antidote Education Company that all individuals in a position to control the content of an activity disclose all financial relationships with any ineligible company to Antidote prior to the activity. A relevant financial relationship is defined as any financial relationship in any amount occurring within the past 24 months with an ineligible company. A relevant financial relationship exists when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he or she has a financial relationship. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Antidote has established mechanisms to mitigate any relevant financial relationships disclosed or otherwise identified to ensure independence in all of its educational activities. If, through the application of these mechanisms, an individual’s relevant financial relationships cannot be resolved, that individual is prohibited from participating in the activity in question in any manner.
The relevant financial relationships, if any, of the individuals in a position to control the content of this educational activity have been mitigated through Antidote’s conflict resolution mechanism. Nonetheless, the relevant financial relationships, if any, of each individual in a position to control the content of this educational activity have been disclosed to you in the following section of this handout entitled “Disclosures.” If an individual has no relevant financial relationships, that fact is also provided to you.
Disclosures
The presenters and planners for this educational activity have disclosed the following relevant financial relationships with ineligible companies:
Allen S. Anderson, MD – Pfizer (Advisor); Bayer, Boehringer Ingelheim, and BridgeBio (Speaker); Edwards Lifesciences (Researcher)
Jose Aristizábal, MD, ISHF – Customed (Consultant)
Kunjan Bhatt, MD – Abbott Laboratories and CVRx, (Consultant); Alleviant Medical (Advisor); AstraZeneca, BridgeBio, and Pfizer, Inc. (Speaker)
Arvind Bhimaraj, MD, MPH, FACC, FHFSA – Abbott Laboratories (Consultant); Abiomed and Cardiol Therapeutics (Researcher); BridgeBio Pharma, Inc., and Pfizer (Advisor); BridgeBio Pharma, Inc. (Speaker). Relationships with BridgeBio Pharma, Inc. and Pfizer have ended.
Yevgeniy Brailovsky, DO, MSc, FACC – AstraZeneca and BridgeBio (Advisor); Pfizer (Research funding)
Robert C. Canby, MD – EBR and Boston Scientific (Advisor); Abbott Laboratories (Researcher); Medtronic (Speaker)
Mario Castillo-Sang, MD – Artivion and Edwards Lifesciences (Consultant); Corcym (Speaker)
John D. Day, MD – Abbott Laboratories and Boston Scientific (Speaker); Kardium (Consultant)
Jeffrey DellaVolpe, MD – Fresenius Medical Care (Advisor)
Gregory Fontana, MD – Abbott Laboratories, Medtronic (Consultant); JenaValve, Medtronic (Advisor); Abbott Laboratories, Edwards Lifesciences, Medtronic, and Pi-Cardia (Research funding (if PI or named investigator). Relationships with Pi-Cardia has ended.
Paul Forfia, MD – Janssen, Merck, United Therapeutics (Consultant)
Hemal Gada, MD, MBA – Abbott Vascular, Boston Scientific Corporation, Edwards Lifesciences, Medtronic, Inc. (Consultant)
Ann Gage MD, MS, FACC – Shifa Med (Researcher); Abiomed and Zoll Fellows Education (Speaker). Relationships with Abiomed and Zoll have ended.
Samuel Horr, MD – Abbott Laboratories, Edwards Life Sciences, Inari Medical, Inc., Inquis Medical (Consultant)
Brian Jefferson MD, FACC, FSCAI – Abbott Vascular, Boston Scientific Corporation, Medtronic, Shockwave Medical (Speaker)
Soma Jyothula, MD – Boehringer Ingelheim (Speaker)
Saibal Kar, MD – Abbott Laboratories (Consultant, Research Funding, and Advisor); Boston Scientific Corporation, Laminar, and Medtronic (Research Funding and Advisor); Pi-Cardia (Ownership Interest: Stock Options)
Neil Keshvani, MD – Heart Sciences, Tricog Health Inc, and Idorsia Pharmaceuticals (Consultant); Science 37 (Consultant). Relationships with Heart Sciences, Tricog Health Inc, and Idorsia Pharmaceuticals have ended.
Matheen Khuddus, MD, FACC, FSCAI – Auryon, Medtronic, Procyrion, and Recor (Advisor); Abbott Vascular, Boston Scientific Corporation, Medtronic, Recor, Shockwave Medical, Inc. (Consultant/Speaker); and Vantis (Ownership interest: Stockholder)
Chelsea King, BSN, RN – Fresenius Medical (Speaker). Relationship with Fresenius Medical has ended.
Chandra Kunavarapu, MD – Inari Medical, Jansen, and Merck (Speaker)
Dhanunjaya Lakkireddy, MD, MBA – Abbott Laboratories, AtriCure, Biosense Webster, Inc., Boston Scientific, Lifetech, and Medtronic (Speaker)
Samuel Leonard, MD – Shockwave (Consultant); Medtronic (Speaker). Relationship with Medtronic has ended.
Jamil A. Malik, MD, FACC, FSCAI – Chiesi (Consultant)
Cindy M. Martin, MD – Abbott Laboratories (Speaker)
Matthew Martinez, MD – BMS, Cytokinetics (Consultant); iRhythm (Speaker). Relationships with iRhythm has ended.
Kara Monday, MD, FACS – Regional Perfusion Services (Advisor)
Ajith Nair, MD – Abbott Laboratories, Impulse Dynamics, Johnson&Johnson, and Natera (Speaker). Relationship with Abbott has ended; Gossamer (Advisor). Relationship with Gossamer has ended.
Andrea Natale, MD –Abbott Laboratories, BIOTRONIK, Boston Scientific Corporation, BWI, Field Medical, Inc., iRhythm Technologies, Medtronic, and Pulse Bioscience (Consultant).
Keith Nguyen, MD, FSCAI – Abiomed, Inc. and Shockwave Medical Inc. (Speaker)
Crystal Pearson, MSN, RN – Fresenius and Institute of ELS (Consultant). Relationship with Fresenius has ended.
Adrien Picod, MD, PhD – 4TEEN4 Pharmaceuticals GmbH (Research Funding)
V. Seenu Reddy, MD, MBA, FACS, FACC – Angiodynamics (Consultant); Atricure, BD, and Solventim (Speaker). Relationships with BD and Solventim have ended.
Sandeep Sahay, MD, MSc – Keros, Merck, and United Therapeutics (Consultant). Relationship with Keros has ended; Johnson & Johnson (Advisor); Pulmovant (Research funding)
Michael C. Siah, MD – Abbott Laboratories, Shockwave (Consultant); Cagent, Limflow (Researcher)
Vasvi Singh, MD, FACC, FASNC, FSCCT – Alnylam, AstraZeneca, BridgeBio, Pfizer (Speaker); CCS, WCG (Consultant); ASNC/Pfizer (Research funding)
Nandish Thukral, MD – Chiesi and Penumbra, Inc. (Speaker)
Art Tongtiplaphol, MD – Flow Therapy (Executive Role)
Andrew Unzeitig, MD – Penumbra (Speaker); Medtronic and Terumo (Consultant)
Jonathan Yang, MD – Abbott Laboratories (Speaker); Atricure (Consultant)
Thomas Zgonis, DPM, FACFAS – Orthofix (Consultant); Wolter Kluwer (Royalties or patent beneficiary)
All of the relevant financial relationships listed for these individuals listed above have been mitigated prior to the start of the conference.
None of the other presenters, planners, and reviewers of this educational activity have relevant financial relationship(s) to disclose with ineligible companies.
